Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4580642
  • Report
  • Region: Global
  • 142 pages
  • Allied Analytics LLP
1 of 4
Aneurysmal subarachnoid hemorrhage (aSAH) is a condition wherein a brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, leading to paralysis or coma, and even death. The National Institutes of Health (NIH) has stated that aneurysmal subarachnoid hemorrhage (SAH) is a worldwide health burden, with high fatality and permanent disability rates.

The global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023. The major factors driving the global aneurysmal subarachnoid hemorrhage market are rise in prevalence of diseases such as stroke and hypertension, and surge in geriatric population. In addition, lifestyle modifications, such as increased alcohol consumption and smoking, further increase the risk for aSAH, which in turn stimulates the market growth. However, the associated side effects of drugs and medication taken during the treatment of aneurysmal subarachnoid hemorrhage restrain the market growth. Furthermore, the growth in awareness about the treatment of the aSAH is expected to provide numerous opportunities for the market growth in future.

The global aneurysmal subarachnoid hemorrhage market is segmented based on drug class and region. Based on drug class, the market is segmented into opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market are Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).

KEY BENEFITS
  • This report provides an extensive analysis of the current and emerging trends, and dynamics in the global aneurysmal subarachnoid hemorrhage drugs market to identify the prevailing opportunities.
  • It presents a competitive landscape of the global market to predict the market scenario across geographies.
  • A comprehensive analysis of factors that drive and restrict the market growth is provided.
  • The region- and country-wise analyses are provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS

By Drug Class
  • Opioid Analgesic
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agent
  • Other Drugs
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
The key players profiled in this report are as follows:
  • Arbor Pharmaceuticals Inc.
  • Edge Therapeutics, Inc.
  • Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
  • Mylan N.V.
  • Orexo AB
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Pharmaxis, Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of stroke and hypertension
3.4.1.3. Lifestyle modifications which increase the risk of aSAH
3.4.2. Restraints
3.4.2.1. Side effects of the drugs
3.4.3. Opportunities
3.4.3.1. Need for growing awareness about the treatment of aSAH
3.4.4. Impact analyses

CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Patients treated, by drug class
4.1.2. Market size and forecast
4.2. Opioid analgesics
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast by region
4.2.3. Market analysis by country
4.3. Calcium channel blockers
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast by region
4.3.3. Market analysis by country
4.4. Anticonvulsants
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast by region
4.4.3. Market analysis by country
4.5. Stool softeners
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast by region
4.5.3. Market analysis by country
4.6. Osmotic agents/diuretics
4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast by region
4.6.3. Market analysis by country
4.7. Other drugs
4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast by region
4.7.3. Market analysis by country

CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION
5.1. Overview
5.1.1. Market size and forecast
5.2. North America
5.2.1. Key market trends, growth factors & opportunities
5.2.2. Market size and forecast by country
5.2.2.1. U.S.
5.2.2.1.1. U.S. aneurysmal subarachnoid hemorrhage market, by drug class
5.2.2.2. Canada
5.2.2.2.1. Canada aneurysmal subarachnoid hemorrhage market, by drug class
5.2.2.3. Mexico
5.2.2.3.1. Mexico aneurysmal subarachnoid hemorrhage market, by drug class
5.2.3. North America market size and forecast by drug class
5.3. Europe
5.3.1. Key market trends, growth factors & opportunities
5.3.2. Market size and forecast by country
5.3.2.1. Germany
5.3.2.1.1. Germany aneurysmal subarachnoid hemorrhage market, by drug class
5.3.2.2. France
5.3.2.2.1. France aneurysmal subarachnoid hemorrhage market, by drug class
5.3.2.3. UK
5.3.2.3.1. UK aneurysmal subarachnoid hemorrhage market, by drug class
5.3.2.4. Italy
5.3.2.4.1. Italy aneurysmal subarachnoid hemorrhage market, by drug class
5.3.2.5. Spain
5.3.2.5.1. Spain aneurysmal subarachnoid hemorrhage market, by drug class
5.3.2.6. Rest of Europe
5.3.2.6.1. Rest of Europe aneurysmal subarachnoid hemorrhage market, by drug class
5.3.3. Europe market size and forecast by drug class
5.4. Asia-Pacific
5.4.1. Key market trends, growth factors & opportunities
5.4.2. Market size and forecast by country
5.4.2.1. Japan
5.4.2.1.1. Japan aneurysmal subarachnoid hemorrhage market, by drug class
5.4.2.2. China
5.4.2.2.1. China aneurysmal subarachnoid hemorrhage market, by drug class
5.4.2.3. Australia
5.4.2.3.1. Australia aneurysmal subarachnoid hemorrhage market, by drug class
5.4.2.4. India
5.4.2.4.1. India aneurysmal subarachnoid hemorrhage market, by drug class
5.4.2.5. South Korea
5.4.2.5.1. South Korea aneurysmal subarachnoid hemorrhage market, by drug class
5.4.2.6. Rest of Asia-Pacific
5.4.2.6.1. Rest of Asia-Pacific aneurysmal subarachnoid hemorrhage market, by drug class
5.4.3. Asia-Pacific market size and forecast by drug class
5.5. LAMEA
5.5.1. Key market trends, growth factors & opportunities
5.5.2. Market size and forecast by country
5.5.2.1. Brazil
5.5.2.1.1. Brazil aneurysmal subarachnoid hemorrhage market, by drug class
5.5.2.2. Saudi Arabia
5.5.2.2.1. Saudi Arabia aneurysmal subarachnoid hemorrhage market, by drug class
5.5.2.3. South Africa
5.5.2.3.1. South Africa aneurysmal subarachnoid hemorrhage market, by drug class
5.5.2.4. Rest of LAMEA
5.5.2.4.1. Rest of LAMEA aneurysmal subarachnoid hemorrhage market, by drug class
5.5.3. LAMEA market size and forecast by drug class

CHAPTER 6: COMPANY PROFILE
6.1. Arbor Pharmaceuticals Inc.
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Key strategic moves and developments
6.2. Edge Therapeutics, Inc.
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Product portfolio
6.2.4. Business performance
6.3. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.4. Mylan N.V.
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.5. Orexo AB
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio
6.5.4. Business performance
6.5.5. Key strategic moves and developments
6.6. Pfizer Inc.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Business performance
6.7. Purdue Pharma L.P.
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Product portfolio
6.7.4. Key strategic moves and developments
6.8. Pharmaxis, Ltd.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance
6.9. Sun Pharmaceutical Industries Ltd.
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance
6.10. Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, "Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 2017-2023" the global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023.

Aneurysmal subarachnoid hemorrhage is a kind of stroke, which is caused by bleeding in the subarachnoid space of the brain. The major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury. Change in lifestyles such as smoking and alcohol consumption increase the risk for aSAH, as well as rise in geriatric population are the major factors that contribute to the growth of the market. Moreover, increase in prevalence of hypertension, and stroke further boost the market growth. However, the associated side effects of the drugs are expected to impede the market growth. In addition, a need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage provide lucrative opportunities for the market growth.

Opioid analgesics generated the maximum revenue, accounting for more than two-fifths share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016. The calcium channel blockers segment is expected to witness the highest CAGR of 4.5% during the forecast period, owing to their ability to reduce the risk of brain damage.

Key findings of the Aneurysmal Subarachnoid Hemorrhage Drugs Market:

The opioid analgesics segment is expected to grow at a significant CAGR of 2.6% during the forecast period.
The anticonvulsants segment contributed nearly one-fourth share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016.
The stool softeners segment is projected to grow at a significant CAGR of 4.2% during the forecast period.
Germany and France are the major shareholders, which collectively accounted for more than one-third share of the European aneurysmal subarachnoid hemorrhage drugs market in 2016.
Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific aneurysmal subarachnoid hemorrhage drugs market in 2016.

The Asia-Pacific market is projected to grow at the highest CAGR of 5.5% during the forecast period, owing to rise in awareness about the treatment of aneurysmal subarachnoid hemorrhage in the healthcare industry and surge in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.

The major companies profiled in the report are Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll